Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict Treatment Response in Depressed Patients
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Increased levels of inflammation have been associated with a poorer response to antidepressants in several clinical samples, but these findings have had been limited by low reproducibility of biomarker assays across laboratories, difficulty in predicting response probability on an individual basis, and unclear molecular mechanisms. METHODS: Here we measured absolute mRNA values (a reliable quantitation of number of molecules) of Macrophage Migration Inhibitory Factor and interleukin-1β in a previously published sample from a randomized controlled trial comparing escitalopram vs nortriptyline (GENDEP) as well as in an independent, naturalistic replication sample. We then used linear discriminant analysis to calculate mRNA values cutoffs that best discriminated between responders and nonresponders after 12 weeks of antidepressants. As Macrophage Migration Inhibitory Factor and interleukin-1β might be involved in different pathways, we constructed a protein-protein interaction network by the Search Tool for the Retrieval of Interacting Genes/Proteins. RESULTS: We identified cutoff values for the absolute mRNA measures that accurately predicted response probability on an individual basis, with positive predictive values and specificity for nonresponders of 100% in both samples (negative predictive value=82% to 85%, sensitivity=52% to 61%). Using network analysis, we identified different clusters of targets for these 2 cytokines, with Macrophage Migration Inhibitory Factor interacting predominantly with pathways involved in neurogenesis, neuroplasticity, and cell proliferation, and interleukin-1β interacting predominantly with pathways involved in the inflammasome complex, oxidative stress, and neurodegeneration. CONCLUSION: We believe that these data provide a clinically suitable approach to the personalization of antidepressant therapy: patients who have absolute mRNA values above the suggested cutoffs could be directed toward earlier access to more assertive antidepressant strategies, including the addition of other antidepressants or antiinflammatory drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“…involved in the prostaglandins and kynurenine pathways, contributes to both the risk of depression and to antidepressant response (Bull et al., 2009; Dowlati et al., 2010; Uher et al., 2010; Bufalino et al., 2013), thus suggesting that a different cluster of individuals expresses high levels of…”
BackgroundAssociations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 1×
“…is supported by a recent randomized controlled trial with the tumor necrosis factor (TNF)- α antagonist, infliximab, providing some evidence that patients with high levels of inflammation are more likely to respond to an adjuvant treatment with antiin-flammatory drugs (Raison et al., 2013).”
BackgroundNanni, V., Uher, R., & Danese, A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020335 · Cited by 1,480
Self-citationAllele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions
Klengel, T., Mehta, D., Anacker, C., Rex-Haffner, M., Pruessner, J. C., Pariante, C. M., Pace, T. W. W., Mercer, K. B., Mayberg, H. S., Bradley, B., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3275 · Cited by 1,447 · cited 1×
“…produce similar epigenetic changes in human blood cells and human neuronal cells, leading to long-term dysregulation of the stress hormone system and global changes in the function of immune cells as well as of brain areas associated with stress regulation (Klengel et al., 2013; Uher et al., 2014).”
BackgroundSelf-citationInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C. M., & Mondelli, V (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.67 · Cited by 1,084
Self-citationSetiawan, E., Wilson, A. A., Mizrahi, R., Rusjan, P. M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J. L., Rekkas, P. V., Houle, S., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2427 · Cited by 939
Nemeroff, C. B., Heim, C. M., Thase, M. E., Klein, D. N., Rush, A. J., Schatzberg, A. F., Ninan, P. T., McCullough, J. P., Weiss, P. M., Dunner, D. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336126100 · Cited by 829
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
Torres-Platas, S. G., Cruceanu, C., Chen, G. G., Turecki, G., & Mechawar, N. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.05.007 · Cited by 545 · cited 1×
“…have found an increased proportion of primed microglia and higher mRNA levels of several chemokines involved in the recruitment of monocytes (Torres-Platas et al., 2014); and a recent neuroimaging study has found increased microglia activation (translocator protein density) using positron…”
BackgroundChildhood maltreatment and inflammatory markers: a systematic review.
Coelho, R., Viola, T. W., Walss‐Bass, C., Brietzke, E., & Grassi‐Oliveira, R. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12217 · Cited by 426
Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388 · cited 1×
“…of monoamine transporters, reduce tryptophan availability, inhibit neuropeptide and growth factors involved in neuroplasticity, and interfere with the kynurenine pathways, leading in turn to a reduction in neurogenesis and glutamate dysfunction (Zunszain et al., 2012; Felger and Lotrich, 2013).”
BackgroundSelf-citationSensing damage by the NLRP3 inflammasome
Leemans, J. C., Cassel, S. L., & Sutterwala, F. S. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01043.x · Cited by 281 · cited 1×
“…(CASP), and nuclear factor kappa-light-chain-enhancer of activated B cells; inter-estingly all of these partners are related to the inflammasome complex or are mediators of oxidative stress, and they are well known to cause neurodegenerative effects (Leemans et al., 2011; Radi et al., 2014).”
BackgroundBull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228 · cited 1×
“…well as in enzymes involved in the prostaglandins and kynurenine pathways, contributes to both the risk of depression and to antidepressant response (Bull et al., 2009; Dowlati et al., 2010; Uher et al., 2010; Bufalino et al., 2013), thus suggesting that a different cluster of individuals…”
BackgroundSelf-citationBufalino, C., Hepgul, N., Aguglia, E., & Pariante, C. M. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.04.009 · Cited by 228 · cited 1×
“…pathways, contributes to both the risk of depression and to antidepressant response (Bull et al., 2009; Dowlati et al., 2010; Uher et al., 2010; Bufalino et al., 2013), thus suggesting that a different cluster of individuals expresses high levels of inflammation and lack of treatment response…”
BackgroundSelf-citationGenetic predictors of response to antidepressants in the GENDEP project
Uher, R., Huezo-Diaz, P., Perroud, N., Smith, R., Rietschel, M., Mors, O., Hauser, J., Maier, W., Kozel, D., Henigsberg, N., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.12 · Cited by 226 · cited 3×
“The GENDEP project is an open-label, part-randomized, multicenter pharmacogenetic study with 2 active pharmacological treatment arms that has been extensively described before (Uher et al., 2009, 2014; Keers et al., 2010; Powell et al., 2012; Cattaneo et al., 2013).”
MethodSelf-citationCarvalho, L. A., Torre, J. P., Papadopoulos, A. S., Poon, L., Juruena, M. F., Markopoulou, K., Cleare, A. J., & Pariante, C. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.036 · Cited by 167
Self-citationMartinez, J. M., Garakani, A., Yehuda, R., & Gorman, J. M. (2012) · Depression and Anxiety · doi:10.1002/da.20876 · Cited by 131
Depression pathogenesis and treatment: what can we learn from blood mRNA expression?
Hepgul, N., Cattaneo, A., Zunszain, P. A., & Pariante, C. M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-28 · Cited by 127
Self-citationFITZGERALD, P., O'BRIEN, S. M., SCULLY, P., RIJKERS, K., SCOTT, L. V., & DINAN, T. G. (2006) · Psychological Medicine · doi:10.1017/s003329170500632x · Cited by 66 · cited 3×
“…tend to have even higher concentrations of these biomarkers, both as plasma/serum proteins (Sluzewska et al., 1997; Lanquillon et al., 2000; Fitzgerald et al., 2006; Rethorst et al., 2013) and as blood mRNA levels (Carvalho et al., 2013; Cattaneo et al., 2013; Lisi et al., 2013; Powell et…”
BackgroundInfluential
Cited by
Köhler, C. A., Freitas, T. H., Stubbs, B., Maes, M., Solmi, M., Veronese, N., de Andrade, N. Q., Morris, G., Fernandes, B. S., Brunoni, A. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0632-1 · Cited by 449
“In addition, a few studies suggest that peripheral immune activation may predict treatment non-response [12, 14].”
What does plasma CRP tell us about peripheral and central inflammation in depression?
Felger, J. C., Haroon, E., Patel, T. A., Goldsmith, D. R., Wommack, E. C., Woolwine, B. J., Le, N.-A., Feinberg, R., Tansey, M. G., & Miller, A. H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0096-3 · Cited by 448
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
Treatment-resistant depression and peripheral C-reactive protein.
Chamberlain, S. R., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D. N. C., Drevets, W. C., Cowen, P. J., Harrison, N. A., Pointon, L., Pariante, C. M., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.66 · Cited by 400
Self-citation
Metadata
- Authors
- Cattaneo, A., Ferrari, C., Uher, R., Bocchio-Chiavetto, L., Riva, M. A., the MRC ImmunoPsychiatry Consortium, & Pariante, C. M.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-05-11
- Volume
- 19
- Issue
- 10
- Pages
- pyw045
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2350135113
- Cited by
- 132
- References
- 23
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.